Burning Rock Biotech (BNR) EBIT Margin (2020 - 2025)
Historic EBIT Margin for Burning Rock Biotech (BNR) over the last 6 years, with Q3 2025 value amounting to 12.26%.
- Burning Rock Biotech's EBIT Margin rose 177400.0% to 12.26% in Q3 2025 from the same period last year, while for Sep 2025 it was 22.97%, marking a year-over-year increase of 633400.0%. This contributed to the annual value of 69.32% for FY2024, which is 552200.0% up from last year.
- Latest data reveals that Burning Rock Biotech reported EBIT Margin of 12.26% as of Q3 2025, which was up 177400.0% from 7.74% recorded in Q2 2025.
- In the past 5 years, Burning Rock Biotech's EBIT Margin ranged from a high of 7.74% in Q2 2025 and a low of 202.9% during Q2 2022
- Over the past 5 years, Burning Rock Biotech's median EBIT Margin value was 135.09% (recorded in 2021), while the average stood at 112.57%.
- Its EBIT Margin has fluctuated over the past 5 years, first crashed by -904600bps in 2021, then surged by 1101600bps in 2024.
- Quarter analysis of 5 years shows Burning Rock Biotech's EBIT Margin stood at 171.11% in 2021, then increased by 11bps to 152.88% in 2022, then grew by 10bps to 137.37% in 2023, then soared by 53bps to 65.01% in 2024, then soared by 81bps to 12.26% in 2025.
- Its EBIT Margin was 12.26% in Q3 2025, compared to 7.74% in Q2 2025 and 11.41% in Q1 2025.